Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201855 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL320610 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL21688461 | 0.88 | ALDH1A1 (0.53) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL5400343 | 0.88 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL10165250 | 0.88 | ALDH1A1 (0.53) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL5400346 | 0.88 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL18651131 | 0.88 | ALDH1A1 (0.53) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Valine SCHEMBL28307488 | 0.87 | SLC15A1 (0.58) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL24859302 | 0.86 | ALDH1A1 (0.51) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL21688727 | 0.86 | ALDH1A1 (0.51) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103923765-A | Detergent Composition For Process Of Manufacturing Semiconductors And Displays | COWON INNOTECH INC | 2014-07-16 | — | — | CN | claimed |
| US-20260109711-A1 | MACROCYCLIC SULFONAMIDE MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | KEYMED BIOSCIENCES (CHENGDU) CO., LTD. (CN) | 2026-01-01 | — | — | US | disclosed |
| US-12478696-B2 | Gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-11-25 | — | — | US | disclosed |
| EP-4623936-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | Keymed Biosciences (Chengdu) Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-20250114485-A1 | GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-04-10 | — | — | US | disclosed |
| US-20240293569-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATE | PINOTBIO, INC. (KR) | 2024-09-05 | — | — | US | disclosed |
| EP-4420684-A1 | DNA TOXIC DIMER COMPOUND AND CONJUGATE THEREOF | Systimmune, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-114409562-B | CA4 derivative and ligand-drug conjugate thereof | 四川百利药业有限责任公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20100286427-A1 | RETINOID PRODRUG COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2196468-A1 | Exo-and diastereo-selective syntheses of himbacine analogs | SCHERING CORPORATION (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| US-20090281321-A1 | EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS | SCHERING CORPORATION | 2009-11-12 | — | — | US | disclosed |
| US-7605275-B2 | Cyclization of 1-(1-(diphenylaminocarbonyl-vinyl-)ethyl-oxycarbonyl-vinyl-),5-nitro-)cyclohex-1-ene by heating in a solvent to form an trans-(5,6)ring junction and an endoisomer(cis) isomer of 3-(oxo),6-(nitro),9-diphenylamido-perhydro-4,4a-didehydronaphtho(2,3)furan | SCHERING CORPORATION (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
| US-20080250535-A1 | METHOD OF SELECTIVELY PRODUCING MALE OR FEMALE STERILE PLANTS | HAWKES TIMOTHY ROBERT | 2008-10-09 | — | — | US | disclosed |
| US-20080085923-A1 | Thrombin Receptor Antagonists Based On The Modified Tricyclic Unit Of Himbacine | SCHERING CORPORATION | 2008-04-10 | — | — | US | disclosed |
| US-20050150013-A1 | Generating sex specific sterility in plants via vector transformation and expression of phytotoxic converting enzymes; hybrid seed production and enhanced crop yields | SYNGENTA LIMITED | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109711-A1 | MACROCYCLIC SULFONAMIDE MODULATORS | HCRTR2, HCRTR1, CNR1 | ALDH1A1 1750/4885TDP1 4616/4885MAPK1 2000/4885 |
| US-12478696-B2 | Gadolinium chelate compounds for use in magnetic resonance imaging | GLRA1, GLRA3, GLRB | ALDH1A1 3811/4885TDP1 1272/4885MAPK1 1678/4885 |
| US-20100286427-A1 | RETINOID PRODRUG COMPOUND | STRA6, RXRA, RXRB | ALDH1A1 701/4885TDP1 4429/4885MAPK1 3960/4885 |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | ALDH1A1 2297/4885TDP1 1942/4885MAPK1 1885/4885 |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | ALDH1A1 2433/4885TDP1 1986/4885MAPK1 1163/4885 |
| US-20240293569-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATE | BCR, IGSF11, STT3B | ALDH1A1 1174/4885TDP1 3934/4885MAPK1 3473/4885 |
| US-20080085923-A1 | Thrombin Receptor Antagonists Based On The Modified Tricyclic Unit Of Himbacine | PTAFR, TBXA2R, BDKRB1 | ALDH1A1 3979/4885TDP1 1468/4885MAPK1 1615/4885 |
| US-20250114485-A1 | GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | GLRA1, GLRA3, GLRB | ALDH1A1 3811/4885TDP1 1272/4885MAPK1 1678/4885 |
| US-20050150013-A1 | Generating sex specific sterility in plants via vector transformation and expression of phytotoxic converting enzymes; hybrid seed production and enhanced crop yields | DDT, DAO, DDO | ALDH1A1 634/4885TDP1 537/4885MAPK1 2521/4885 |
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | HCCS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | ALDH1A1 516/4885TDP1 2954/4885MAPK1 3604/4885 |
| US-20090281321-A1 | EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS | EDNRA, EDNRB, NMBR | ALDH1A1 4387/4885TDP1 1793/4885MAPK1 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.